The Berlin-based biotech company Berlin Cures is conducting research into a new method for protection against corona viruses. The idea: the active ingredient BC007, which belongs to the drug group of aptamers, is to be absorbed in the form of a nasal spray or inhaler and prevent the virus from entering healthy cells. Should the virus nevertheless penetrate, the drug could stop or slow down the multiplication of the virus. Johannes Mueller, managing director of Berlin Cures, sees the active substance thus for the prophylaxis as well as for the treatment with a positive test result with light COVID 19 symptoms suitably. According to initial studies, BC007 should not have any side effects, but the company is still at least six months away from developing the drug to market maturity. Müller regrets that, in contrast to the development of vaccines, research into drugs for the treatment of coronaviruses is currently receiving little support. Whether Berlin Cures active substance will nevertheless be approved for further test phases cannot be ruled out at present.
Quelle: stern.de